GlaxoSmithKline and Kyowa Hakko Kirin said on November 22 that they have inked a strategic collaboration in Japan for the commercialization of daprodustat, the UK firm’s investigational treatment for anemia associated with chronic kidney disease (CKD). The deal illustrates a…
To read the full story
Related Article
- Nesp’s Biosame Switches Rapid but Expected: Kyowa Kirin President
February 7, 2020
- GSK’s Daprodustat Reaches 1st NDA Filing, in Japan
August 22, 2019
BUSINESS
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
August 7, 2026
- Meiji Pharma Drops Hiyasta Development in B-Cell NHL
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





